Cross-source identity
National Provider Identifier 1336508423 as it appears in every federal dataset Fonteum holds. Each row is a distinct public source; the chip carries the source and the snapshot date behind that field — the record-level form of the source-provenanced graph.
| Federal source | Key | What it provides | Provenance |
|---|
| CMS NPPES | NPI 1336508423 | Registry identity — psychiatrist, taxonomy 2084P0800X | Source:CMS NPPESSnapshot 2026-05-06 |
| CMS Open Payments | NPI 1336508423 | 343 industry-payment records, 2024 | Source:CMS Open PaymentsSnapshot PY2024 |
| CMS Medicare Part D | NPI 1336508423 | 74 drugs prescribed, 2024 | Source:CMS Part DSnapshot DY2024 |
| Fonteum entity graph | entity bb1ae932… | Canonical resolved node · 2 identifier(s) · 4 edge(s) | Source:Entity graphSnapshot 2026-06-11 |
Industry payments
Payments and transfers of value this clinician received from drug and device manufacturers, disclosed under the Physician Payments Sunshine Act. A payment is a disclosure, not a judgment.
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $115,700 | 65 |
| Consulting Fee | $42,261 | 12 |
| Travel and Lodging | $18,725 | 61 |
| Food and Beverage | $8,758 | 203 |
| Education |
| Manufacturer | Amount | Records |
|---|---|---|
| Teva Pharmaceuticals Usa, Inc. | $74,672 | 125 |
| E.R. Squibb & Sons, L.L.C. | $36,938 | 51 |
| Neurocrine Biosciences, Inc. | $26,260 |
Prescribing
Prescriptions written under Medicare Part D, aggregated by drug across the program. Totals reflect claims paid, not patients treated.
| Drug | Claims | Drug cost |
|---|---|---|
| Invega Sustenna(Paliperidone Palmitate) | 140 | $460,203 |
| Austedo Xr(Deutetrabenazine) | 31 | $303,719 |
| Uzedy(Risperidone) | 63 | $225,867 |
| Caplyta(Lumateperone Tosylate) | 78 | $128,652 |
| Ingrezza(Valbenazine Tosylate) | 15 | $123,086 |
Beneficiary counts below 11 are suppressed by CMS — the total shown is a lower bound.
Quality
CMS Quality Payment Program Merit-based Incentive Payment System (MIPS) final score, where this clinician participated. Absence of a score is not a quality signal — many clinicians report through a group or are exempt.
Enrollment & sanctions
Screening aid — re-confirm any match against the issuing list before acting. A clean result means no record was found in the federal OIG LEIE or the state Medicaid lists Fonteum currently holds (NY, OH, GA), not a guarantee that none exists elsewhere. Not a legal or credentialing certification.
Ownership & affiliations
One-hop relationships in the resolved entity graph — chain membership, ownership, and operation edges, each backed by a federal source row. Most individual clinicians carry none; edges populate for owners and organizations as the Lane D backfill runs.
| Relationship | Entity | Source |
|---|---|---|
| ← pays | Janssen Pharmaceuticals, Inc (NJ) | cms_open_payments |
| ← pays | Janssen Scientific Affairs, Llc (NJ) | cms_open_payments |
| ← pays | E.R. Squibb & Sons, L.L.C. (NJ) | cms_open_payments |
| ← pays | Eisai Inc. (NJ) | cms_open_payments |
| 2 |
| 39 |
| Axsome Therapeutics, Inc. | $21,628 | 33 |
| Otsuka America Pharmaceutical, Inc. | $18,442 | 40 |